Drug Profile
Allogeneic stem cell therapy - Stematix
Alternative Names: AllostromeLatest Information Update: 31 Oct 2021
Price :
$50
*
At a glance
- Originator Stematix
- Class Cardiovascular therapies; Mesenchymal stem cell therapies; Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cartilage disorders; Joint disorders; Myocardial infarction
Most Recent Events
- 23 Jan 2018 No development reported - Phase-II for Cartilage disorders in USA (Parenteral)
- 23 Jan 2018 No development reported - Phase-II for Joint disorders in USA (Parenteral)
- 23 Jan 2018 No development reported - Phase-III for Myocardial infarction in USA (Parenteral)